ProteKt secures funding for PKR kinase inhibitor-based therapies
Israeli biotech company ProteKt Therapeutics, which is focused on developing new PKR kinase inhibitor-based therapies for Alzheimer’s Disease and other neurodegenerative diseases, has secured $3.6 million in post-incubation financing. The financing was led jointly by Canadian capital development fund Fonds de solidarité FTQ and South Korean pharma company Bukwang Pharmaceutical. Existing investors – FutuRx, OrbiMed, […]